Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid levels in patients who receive secondary prevention of cardiovascular diseases (CVD) and require enhanced lipid-lowering therapy.Material and methods. The study included 49 patients (ag...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2020-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227624832827392 |
|---|---|
| author | A. E. Nikitin E. E. Averin D. E. Rozhkov A. V. Sozykin G. A. Procenko |
| author_facet | A. E. Nikitin E. E. Averin D. E. Rozhkov A. V. Sozykin G. A. Procenko |
| author_sort | A. E. Nikitin |
| collection | DOAJ |
| description | Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid levels in patients who receive secondary prevention of cardiovascular diseases (CVD) and require enhanced lipid-lowering therapy.Material and methods. The study included 49 patients (aged of 61.53±1.14 years; 31 [63.3%] men) receiving alirocumab who did not reach the target low density lipoprotein cholesterol (LDL-C) concentrations despite the ongoing optimal lipid-lowering therapy. In all patients, the initial level of lipids was evaluated, as well as their parameters after subsequent alirocumab injections.Results. LDL-C serum level significantly decreased after the first injection compared to the initial level from 2.92±0.22 to 1.65±0.19 mmol/L (p<0.001; Δ45.31±3.61%) and down to 1.74±0.17 mmol/L for the entire study period (p<0.001; Δ41.52±2.69%). The change in LDL-C level between injections did not show statistically significant differences (p=0.141). A direct strong statistically significant correlation between the LDL-C level after the first injection and its average values for the entire observation period was found (r=0.958, p<0.001).Conclusion. The results of the study indicate that the PCSK9 inhibitor, alirocumab, in patients who need secondary prevention of CVD shows a significant additional decrease in the concentration of LDL-C after the first injection. At the same time, approximately half of the patients were able to achieve the recommended levels of LDL-C. The persistence of the achieved low LDL-C levels over time demonstrated that the average concentration of LDL-C during the observation corresponded to the values after the first injection. This finding shows that there is no need for constant monitoring of lipid metabolism parameters when prescribing such therapy. |
| format | Article |
| id | doaj-art-0204f048f1134c66a2d43aad9109bfdc |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2020-03-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-0204f048f1134c66a2d43aad9109bfdc2025-08-23T10:00:31ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532020-03-01161333910.20996/1819-6446-2020-02-061699Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular DiseaseA. E. Nikitin0E. E. Averin1D. E. Rozhkov2A. V. Sozykin3G. A. Procenko4Central Clinical Hospital of the Russian Academy of SciencesCentral Clinical Hospital of the Russian Academy of SciencesCentral Clinical Hospital of the Russian Academy of SciencesCentral Clinical Hospital of the Russian Academy of SciencesCentral Clinical Hospital of the Russian Academy of SciencesAim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid levels in patients who receive secondary prevention of cardiovascular diseases (CVD) and require enhanced lipid-lowering therapy.Material and methods. The study included 49 patients (aged of 61.53±1.14 years; 31 [63.3%] men) receiving alirocumab who did not reach the target low density lipoprotein cholesterol (LDL-C) concentrations despite the ongoing optimal lipid-lowering therapy. In all patients, the initial level of lipids was evaluated, as well as their parameters after subsequent alirocumab injections.Results. LDL-C serum level significantly decreased after the first injection compared to the initial level from 2.92±0.22 to 1.65±0.19 mmol/L (p<0.001; Δ45.31±3.61%) and down to 1.74±0.17 mmol/L for the entire study period (p<0.001; Δ41.52±2.69%). The change in LDL-C level between injections did not show statistically significant differences (p=0.141). A direct strong statistically significant correlation between the LDL-C level after the first injection and its average values for the entire observation period was found (r=0.958, p<0.001).Conclusion. The results of the study indicate that the PCSK9 inhibitor, alirocumab, in patients who need secondary prevention of CVD shows a significant additional decrease in the concentration of LDL-C after the first injection. At the same time, approximately half of the patients were able to achieve the recommended levels of LDL-C. The persistence of the achieved low LDL-C levels over time demonstrated that the average concentration of LDL-C during the observation corresponded to the values after the first injection. This finding shows that there is no need for constant monitoring of lipid metabolism parameters when prescribing such therapy.https://www.rpcardio.online/jour/article/view/2123atherosclerosissecondary preventioncardiovascular diseasetarget levellow density lipoprotein cholesterolpcsk9 inhibitorsalirocumab |
| spellingShingle | A. E. Nikitin E. E. Averin D. E. Rozhkov A. V. Sozykin G. A. Procenko Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease Рациональная фармакотерапия в кардиологии atherosclerosis secondary prevention cardiovascular disease target level low density lipoprotein cholesterol pcsk9 inhibitors alirocumab |
| title | Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease |
| title_full | Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease |
| title_fullStr | Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease |
| title_full_unstemmed | Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease |
| title_short | Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease |
| title_sort | alirocumab administration experience to achieve low density lipoprotein cholesterol target levels in secondary prevention of cardiovascular disease |
| topic | atherosclerosis secondary prevention cardiovascular disease target level low density lipoprotein cholesterol pcsk9 inhibitors alirocumab |
| url | https://www.rpcardio.online/jour/article/view/2123 |
| work_keys_str_mv | AT aenikitin alirocumabadministrationexperiencetoachievelowdensitylipoproteincholesteroltargetlevelsinsecondarypreventionofcardiovasculardisease AT eeaverin alirocumabadministrationexperiencetoachievelowdensitylipoproteincholesteroltargetlevelsinsecondarypreventionofcardiovasculardisease AT derozhkov alirocumabadministrationexperiencetoachievelowdensitylipoproteincholesteroltargetlevelsinsecondarypreventionofcardiovasculardisease AT avsozykin alirocumabadministrationexperiencetoachievelowdensitylipoproteincholesteroltargetlevelsinsecondarypreventionofcardiovasculardisease AT gaprocenko alirocumabadministrationexperiencetoachievelowdensitylipoproteincholesteroltargetlevelsinsecondarypreventionofcardiovasculardisease |